Genedata Biologics®は、二重特異性抗体、抗体薬物複合体（ADC）、T細胞受容体（TCR）、キメラ抗原受容体（CAR-T）をはじめとするバイオ医薬品の創薬ワークフロー全体を統合・効率化します。真のイノベーションに注力できる、業界内で最も広く導入されているプラットフォームです。
Our Customers
One of the reasons we chose Genedata Biologics was the platform’s process coverage. We required that the full diversity of Pfizer’s large-molecule processes and technologies be supported by one integrated system.
We decided to work with Genedata Biologics because it meets our requirements across all phases of biologics discovery, including novel multi-specific antibody formats and innovative automation methods.
Simon Chell, Ph.D.
Vice President of Biologics Engineering
Genedata Biologics gives all our R&D groups a central place to record and access TCR-related information in real time, along the end-to-end workflow.
We are excited to implement the Genedata Biopharma Platform as a central integrated data backbone to streamline the capture, integration, democratization, and analysis of increasingly complex and diverse data types across Genmab’s discovery and clinical workflows.
We undertook a thorough selection process to find the best antibody workflow platform and Genedata Biologics was the obvious choice.
Genedata Biologics was the clear choice as a backbone system to support the full diversity of our complex and rapidly evolving antibody discovery processes.
We made a decision early on to use Genedata Biologics as MorphoSys’ workflow backbone to accelerate our drug discovery efforts and have watched as Genedata Biologics has become the global industry standard for biopharma discovery organizations.
Genedata seamlessly integrates into an existing research informatics environment and supports the full process through automation, standardization, and integration.
The Genedata platform is the core knowledge management system for our global Biologics Engineering organization, helping us to streamline our research with the aim of developing novel therapies, faster.
Simon Chell, Ph.D.
Vice President of Biologics Engineering
Genedata Biologics is a key component of our growth plans in the immuno-oncology and next-generation ADC space.
Genedata Biologics was the obvious choice because it is a proven, off-the-shelf enterprise platform that can be rapidly deployed across our organization.
A commercial data management solution such as this has been sorely lacking in protein therapeutics.
We appreciate Genedata Biologics’ flexible business model, which made it possible for a company of our size to adopt a market-leading platform solution.
Genedata Biologics will be our central repository for mission-critical data on therapeutic candidates such as bioactivity, developability, and manufacturability, and will enable transparent decision-making on candidates to move forward.
Thanks to Genedata’s flexible business model, we are able to take advantage of Genedata’s unique technology under terms that work well for a company of our size.
Advancing Bispecific Antibody Discovery
Advance bispecific antibody discovery and automate downstream expression, purification, and characterization processes to substantially increase throughput.
By identifying the most successful combination of antigen binders and formats, Genedata resolves major bottlenecks and enables the systematic design, cloning, and testing of large numbers of bi- and multi-specifics, such as knobs-into-holes (KinH), Fab-scFv, IgG-scFv, DuoBody, DVD-Ig, tandem-scFv-Fc and their parametric variants (e.g., linkers, V-domain order, Fc).
Learn More
CARs/TCRs
Streamline cell therapy R&D with purpose-built functionalities for the design and evaluation of large panels of cell-based therapeutic modalities for novel immunotherapies.
By directly integrating with laboratory equipment, Genedata fully automates sample handling and testing procedures. The database and tools support screening and engineering of any format such as chimeric antigen receptors T cells (CAR-T), T Cell Receptor Technology (TCRs), and antibody TCR-mimetics (e.g., dsTCR, TCR-scFv, bispecific TCRs).
Learn More
AAVs
Accelerate gene therapy R&D by covering the entire gene therapy workflow, from serotype optimization and viral vector design to virus packaging, purification, and testing.
Genedata tracks all samples and associated information, including customized vectors, packaging plasmids, cell lysates, purified virus batches and their sequences, titers, and assay results such as empty-to-full capsid ratios. Additionally, it supports diverse viral delivery systems including AAV, adenovirus, and retrovirus vectors.
Learn More
ADCs
Enable the registration and tracking of large panels of ADC candidates and manage all linker and payload information (e.g., cytotoxic small molecules) by incorporating results from analytics and functional assays in one integrated platform.
Genedata optimizes the full ADC discovery process from antibody screening and engineering to antibody expression, purification, drug conjugation, and reporting of ADC-specific analytics (e.g., DAR, drug distribution, homogeneity).
Learn More
Vaccines
Enable novel vaccine discovery by increasing efficiency, facilitating faster testing, simplifying production, ensuring quality, and reducing costs.
Genedata supports novel vaccine technologies such as synthetic self-amplifying mRNA, which accelerates vaccine development by utilizing synthetic and cell-free processes and antigen production, in addition to all classic vaccine R&D.
Learn More
RNA Therapeutics
Accelerate end-to-end the design and development of RNA therapeutics and vaccines by leveraging a platform that registers, tests, and evaluates nucleic acid-based therapeutics and vaccines at every stage of development, including RNA/DNA optimization for effectiveness and stability.
Combined with powerful screening workflow tools for formulation development and functional characterization, the platform provides a critical data infrastructure to enable the development of RNA therapeutics faster.
Learn More
B-Cells
Facilitate B cell-derived therapeutic antibody R&D by streamlining every stage of the highly complex B cell-based discovery process. Genedata tracks animal and immunization data and registers all molecules, samples, quality control, and functional assay data on a central integrated platform.
ELISA, FACS, and SPR experiments are also managed on the platform. In combination with V-region sequencing results, this allows the unique integration of molecule sequence and functional information.
Learn More
Developability
Minimize developability and manufacturability risks by incorporating a systematic assessment of the developability risk profile and critical quality attributes (CQA) of any candidate to decide on the most promising ones to move into development.
The platform assesses a drug’s manufacturability by flagging potential problems such as those during expression and purification and evaluates properties that affect molecule robustness on a biophysical and biochemical level.
Learn More
Screening
Designed to enable fully automated, high-throughput screening of biotherapeutic candidates, the software captures, integrates, processes, and interprets selection and screening data derived from diverse discovery technologies, including phage and yeast display, B-cell cloning, and hybridoma.
With built-in sample tracking via integrated plate management functionalities, the platform dramatically increases the efficiency of the early discovery process for antibodies, bi- and multi-specifics, fusion proteins, TCRs, CAR-Ts, and other new modalities.
Learn More
Engineering
The software enables efficient engineering of virtually any protein format and the generation of combinatorial libraries from known molecule building blocks. It utilizes built-in tools for designing and optimizing IgGs as well as complex next-generation antibody formats such as bi- and multi-specifics.
The software supports simultaneous improvement of candidate properties such as binding affinity, cross-reactivity, stability, expressibility, and other critical attributes. Advanced tools for affinity maturation, site-directed mutagenesis, germlining, humanization, reformatting, and isotype switching enable rapid and reliable generation of superior protein variants.
Learn More
Production
For increased efficiency of the entire protein production process, the software tracks and validates individual steps from the initial definition of the proteins to be produced to the final, fully characterized high-quality samples, including all protein expression and purification batches, as well as vector and cell line batches.
Analytical characterization and QC data such as LC-MS, SEC, HIC, endotoxin levels, glycosylation profiles, and functional data from in vivo assays, are aggregated and directly linked to their respective samples. Certificates of Analysis (CoA) and other relevant sample reports are automatically generated using built-in tools.
Request
The software improves operational efficiency and overall monitoring of R&D operations by supporting the full life cycle of task scheduling. Used to submit and track requests from initiation through completion, it manages intra- and intergroup communications and centrally documents the progression of request fulfillment in real time.
Learn More
Meet BIOLOGICS Customers
From large enterprise-wide deployments to single group installations, discover how Genedata Biologics® is used by leading global biopharma, biotechs, CROs, and CRDMOs to increase efficiency and drive innovation.
バイオ医薬品の創薬をサポート
お問い合わせE2E 次世代プラットフォーム
Genedata Biologicsは、ライブラリデザインから動物での抗体作製～セレクション～スクリーニング～タンパク質工学～発現～精製～製品分析まで、研究開発プロセス全てを統合し、分子生物学的およびタンパク質工学的な視点から候補薬の開発・製造可能性の評価を可能にするEnd-to-End（E2E）データプラットフォームです。多種多様かつ膨大なデータを管理し、創薬プロセスの完全自動化を実現します。また、共有プラットフォームのため、研究所拠点間・グループ間、さらにはCROなどの外部パートナーとの連携も容易にします。組織の全てのユーザーが全てのデータへリアルタイムにアクセス可能なため、データをもとに迅速に決断を下すことができ、将来の創薬プログラムに向けたデータパターンの分析も可能です。
日常業務の自動化、
更なるイノベーションへ
Genedata Biologicsは、クローニング・スクリーニング・発現・精製・サンプル管理など日常的なラボ業務を大幅に簡素化し、全てのデータのアップロード・処理・レポート作成を自動化します。また、分析機器やロボットシステムと直接統合することで、真のハイスループットプロセスを実現します。ラボ業務にかける労力を50%以上削減し、データの質を改善できたユーザー企業もあります。
リソース最適化、生産性向上、
リスク削減
Genedata Biologicsは、データを一元管理する共有プラットフォームのため、全ての研究開発チームが全ての創薬プロジェクトの情報へいつでもアクセス可能です。これにより、プロジェクトを横断して同時並行で探索を進めることができ、プログラム進捗の記録やリソース活用の最適化が可能になり研究開発計画の改善、コストの削減、生産性の向上が見込まれます。
